Comparison of Two Oral Iron Formulations for Iron Deficiency and Iron Deficiency Anemia in Inflammatory Bowel Disease: A Prospective Study.

ABSTRACT:

Introduction

The use of oral iron in iron deficiency (ID) and ID anemia (IDA) in inflammatory bowel disease (IBD) is controversial. Its lower cost and ease of administration must be weighed against side effects and efficacy. The aim of this study was to compare the efficacy and tolerability of two oral iron formulations (Sucrosomial® iron [SI] and ferric hydroxide-polymaltose complex [FHPC] for correcting ID and IDA in IBD. As a secondary objective, we aimed to assess the impact of oral iron on correcting ID, IDA, and disability in IBD.

Methods

This was a prospective, observational, bicentric cohort study. We included patients with IBD diagnosed with ID or IDA between November 2022 and November 2023. Physicians were preassigned by the investigators to prescribe SI or FHPC. T

SUBMITTER: Guimaraes A 

PROVIDER: S-EPMC12788864 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature